SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Markevam B.)
 

Sökning: WFRF:(Markevam B.) > A phase II trial of...

  • Samuelsson, J.Karolinska Institutet,Department of Medicine, Stockholm South Hospital, Stockholm, Sweden, Department of Medicine, Stockholm South Hospital, Karolinska Institute, S-118 83 Stockholm, Sweden (författare)

A phase II trial of pegylated interferon a-2b therapy for polycythemia vera and essential thrombocythemia : Feasibility, clinical and biologic effects, and impact on quality of life

  • Artikel/kapitelEngelska2006

Förlag, utgivningsår, omfång ...

  • 2006-04-25
  • Wiley,2006
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-50216
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-50216URI
  • https://doi.org/10.1002/cncr.21900DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-80782URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1956442URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • BACKGROUND. Conventional interferon-a (IFN) is an effective treatment for patients with myeloproliferative disorders. However, many patients discontinue therapy because of side effects. METHODS. In this 24-month, Phase II feasibility study of pegylated interferon a-2b (PEG-IFN) treatment, a starting dose of 0.5 µg/kg per week was received by 21 patients with polycythemia vera (PV) and 21 patients with essential thrombocythemia (ET). The treatment objective, a complete platelet response (CR), was a platelet count <400 × 109/L in symptomatic patients and <600 in asymptomatic patients. Neutrophil polycythemia rubra vera-1 (PRV-1) messenger RNA expression was analyzed prior to and during therapy. Quality of life (QoL) was investi-gated by using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire. RESULTS. At 6 months, 29 of 42 patients (69%) had achieved a CR after a median of 83 days. The CR rate was not related to diagnosis, gender, or previous therapy. Nineteen patients completed the planned 2-year treatment in CR. No thromboembolic or bleeding complications were observed. Phlebotomy requirements were reduced in the majority of patients with PV. Five of 14 patients (36%) who initially were positive for PRV-1 achieved normalized PRV-1 expression under PEG-IFN treatment. Side effects were the cause of therapy failure in 16 of 23 patients. However, only 8 of 19 patients reported any side effects at 2 years. The QLQ-C30 revealed clinically significant impairments in several aspects of QoL at 6 months, however, at 2 years, QoL measurements were not different from baseline. CONCLUSIONS. PEG-IFN effectively reduced platelet counts in 29 of 42 patients, but only 19 patients maintained a CR at 2 years. The reversal of PRV-1 positivity noted in a subset of patients suggested that PEG-IFN may have an effect on the malignant clone. PEG-IFN is a valuable therapeutic alternative for patients who tolerate its initial side effects. © 2006 American Cancer Society.

Ämnesord och genrebeteckningar

  • a-interferon
  • Essential thrombocythemia
  • Myeloproliferative
  • Pegylated
  • Polycythemia rubra vera-1
  • Polycythemia vera
  • Quality of life
  • NATURAL SCIENCES
  • NATURVETENSKAP
  • MEDICINE

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Hasselbalch, H.Department of Medicine, Roskilde University Hospital, Roskilde, Denmark,Department of Experimental Anesthesiology, University Hospital Freiburg, Freiburg, Germany (författare)
  • Bruserud, O.Department of Hematology, Haukeland University Hospital, Bergen, Norway (författare)
  • Temerinac, S.Department of Experimental Anesthesiology, University Hospital Freiburg, Freiburg, Germany (författare)
  • Brandberg, Y.Karolinska Institutet,Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden (författare)
  • Merup, M.Karolinska Institutet,Hematology Center, Karolinska University Hospital, Stockholm, Sweden (författare)
  • Linder, O.Department of Medicine, University Hospital, Orebro, Sweden (författare)
  • Bjorkholm, M.Hematology Center, Karolinska University Hospital, Stockholm, Sweden,Department of Medicine, University Hospital, Umea, Sweden (författare)
  • Pahl, H.L.Department of Experimental Anesthesiology, University Hospital Freiburg, Freiburg, Germany (författare)
  • Birgegard, G.Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi,Department of Medicine, University Hospital, Uppsala, Sweden (författare)
  • Ghanima, W.Department of Medicine, Ostfold-Fredriksstads Hospital, Fredriksstad, Norway (författare)
  • Gram-Hansen, P.Department of Hematology, Odense University Hospital, Odense, Denmark (författare)
  • Johansson, P.Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden (författare)
  • Malm, C.Department of Hematology, University Hospital, Linkoping, Sweden (författare)
  • Markevam, B.Department of Medicine, University Hospital, Umea, Sweden (författare)
  • Mourits-Andersen, T.Department of Medicine, Esbjerg Hospital, Esbjerg, Denmark (författare)
  • Nillson, L.Department of Hematology, Lund University Hospital, Lund, Sweden (författare)
  • Karolinska InstitutetDepartment of Medicine, Stockholm South Hospital, Stockholm, Sweden, Department of Medicine, Stockholm South Hospital, Karolinska Institute, S-118 83 Stockholm, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Cancer: Wiley106:11, s. 2397-24050008-543X1097-0142

Internetlänk

Hitta via bibliotek

  • Cancer (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy